ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
As of March 2026, ELVN-001 produced meaningful responses in heavily pretreated patients, many of whom had already tried multiple existing therapies, Enliven Therapeutics said. Enliven Therapeutics also announced it has aligned with the U.S. Food and Drug Administration (FDA) on key elements of its planned late-stage trial. Separately, Enliven priced an upsized public offering to … Read more